U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 1

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with letter dated December 21, 2018.	4. Expiration Date: November 30, 2033
1. San Cristobal Oncology Services, Inc. 2. P.O. Box 801211 Coto Laurel, PR 00780	3. License number: 52-35511-01 is amended in its entirety to read as follows:	5. Docket No.: 030-39138 Reference No.:

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As Needed	A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As Needed	B. For use in imaging and localization studies permitted by 10 CFR 35.200.
C. Iodine-125 permitted by 10 CFR 35.400	C. Sealed Sources (Theragenics Corporation, Model AgX-100)	C. 4 curies total	C. For any manual brachytherapy procedure permitted by 10 CFR 35.400 for which the patient can be released under the provisions of 10 CFR 35.75.

CONDITIONS

10. Licensed material may be used or stored at the licensee's facilities located at 1000 Tito Castro Boulevard, Ponce, Puerto Rico.

MATERIALS LICENSE SUPPLEMENTARY SHEET	License Number 52-35511-01	Docket or Reference Number 030-39138
	Amendment No. 1	

11. The Radiation Safety Officer (RSO) for this license is Carmelo Perez.

12. Licensed material shall only be used by, or under the supervision of:

A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.

B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized Users	Material and Use
Jose N. Correa, M.D.	10 CFR 35.400
Miguel A. Serpa, M.D.	10 CFR 35.100,10 CFR 35.200

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

UNITED STATES NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE SUPPLEMENTARY SHEET	License Number 52-35511-01	Docket or Reference Number 030-39138
	Amendment No. 1	

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Letter dated October 30, 2018 (except HDR) [ML18311A099]
B. Letter dated November 8, 2018 (except HDR) [ML18317A212]
C. Letter dated November 9, 2018 (except HDR) [ML18323A123]
D. Letter dated December 21, 2018 (except HDR) [ML1901A233]
E. Letter dated February 20, 2019

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: March 14, 2019

By: Farrah C. Gaskins

Farrah Gaskins
Region 1